Avecure Flexible Microwave Ablation Probe For Lung Nodules

Launched by BETH ISRAEL DEACONESS MEDICAL CENTER · Mar 11, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new device called the AveCure Flexible Microwave Ablation Probe, which aims to help destroy cancerous lung nodules that are up to 3 centimeters in size. It is specifically designed for patients with Stage I or II primary lung cancer. The trial is currently recruiting participants who are at least 22 years old, have a confirmed diagnosis of lung cancer with a suitable nodule, and are eligible for surgery.

If you or a loved one are considering participating, you can expect to undergo a procedure using this microwave ablation technique, which uses heat to target and destroy the cancerous tissue. However, there are some criteria that may exclude you from joining, such as having a nodule smaller than 1 centimeter or a medical condition that could affect your safety during the procedure. It's also important to note that participants cannot be pregnant or breastfeeding, and those with certain medical devices or ongoing treatments for lung cancer may not be eligible. This study could offer a new treatment option for managing lung cancer, so it's worth discussing with your healthcare provider if you think you might qualify.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subject with Stage I - II primary lung cancer (Solitary nodules up to 3 cm) as defined by previous pathology or ROSE.
• • Pathological proof of target nodule/tumor type and malignancy with specimen considered adequate per institutional laboratory standards
• • Target nodule/tumor which can be accessed via navigational bronchoscopy and confirmed location with cone beam CT scan intra-operatively
• • Resection/surgical candidate (lobectomy or greater)
• • Participants must be at least 22 years old and able to provide consent
• Exclusion Criteria:
• • Subjects in whom flexible bronchoscopy is contraindicated
• • Target nodule \< 1.0 cm
• • Prior radiation or neo adjuvant chemotherapy of the target nodule/tumor
• • Any comorbidity that the investigator feels would interfere with the safety of the subject or the evaluation of study objectives
• • Pacemaker, implantable cardioverter, or another electronic implantable device
• • Patient cannot tolerate bronchoscopy
• • Patients with coagulopathy
• • Patients in other therapeutic lung cancer studies
• • Subject is pregnant or breastfeeding
• • COVID-19 positive patient at the time of procedure.